1/31
07:46 am
ogn
Organon & Co. (NYSE:OGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
Organon & Co. (NYSE:OGN) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/31
01:33 am
ogn
1/29
07:30 am
ogn
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
Medium
Report
Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026
1/28
12:45 pm
ogn
Organon Completes Divestiture of JADA® System to Laborie
Low
Report
Organon Completes Divestiture of JADA® System to Laborie
1/16
09:12 pm
ogn
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
Medium
Report
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque
1/15
07:52 pm
ogn
Organon (OGN) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
Low
Report
Organon (OGN) Exceeds Market Returns: Some Facts to Consider [Yahoo! Finance]
1/8
01:30 am
ogn
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
Low
Report
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
1/3
01:08 am
ogn
Low
Report
12/10
07:18 am
ogn
Organon & Co. (NYSE:OGN) was upgraded by analysts at Barclays PLC to a "strong sell" rating.
Medium
Report
Organon & Co. (NYSE:OGN) was upgraded by analysts at Barclays PLC to a "strong sell" rating.
12/9
09:06 am
ogn
Organon & Co. (NYSE:OGN) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $7.50 price target on the stock.
Medium
Report
Organon & Co. (NYSE:OGN) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $7.50 price target on the stock.
12/1
10:24 am
ogn
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
Low
Report
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
11/25
07:30 am
ogn
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
Medium
Report
Organon To Present at the Piper Sandler 37th Annual Healthcare Conference
11/17
09:06 am
ogn
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Low
Report
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
11/17
05:30 am
ogn
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
Low
Report
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
11/14
06:36 pm
ogn
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN
Low
Report
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co. - OGN